Ascentage Pharma Group International has announced the release of results from multiple clinical studies at the 2025 European Hematology Association (EHA) Hybrid Congress. The company presented findings from 13 studies focusing on its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918. Notably, olverembatinib demonstrated significant therapeutic potential and clinical benefits in treating Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia $(ALL)$, with high complete remission and molecular response rates. Additionally, a preclinical study on APG-5918 showed its potent antitumor activity in T-cell lymphoma, supporting further clinical development. The results were featured in various formats, including poster presentations at the congress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.